Sunday, August 28, 2016 3:11:52 AM
1. NNVC does in fact select a candidate for ocular Herpescide by the end of this year. That is all they expect to accomplish according to their SEC filings. And of course NNVC has never yet met any of their own time tables. So far we have no indication that any samples have even gone out to any of the universities doing the testing, so this optimistic time table requires that an awful lot be done in the next four months after 8 months of no discernable progress.
2. Then the best we can hope for is that NNVC somehow gets tox done before 2017 is over. Remember that in 2014 it took a full year to make 200g of Flucide (nowhere near enough to complete tox) and then do the little bit of tox testing that could be done with that 200g. So I say one full year to get Herpescide tox done. Minimum.
3. So, we will be at the end of 2017 with no clinical trials in sight. But wait -- NNVC can't do clinical trials until it gets IND approval from the FDA. Figure at least 6 months for this -- it involves the federal government.
So, like I said, no clinical trials for Herpescide in 2016 or 2017. Bank on it. There's a very good chance that there will be no clinical trials in 2018, either, as NNVC typically misses its time tables by factors of 2 or more.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM